InvestorsHub on MSN
Ceribell shares advance after FDA grants breakthrough device status
CeriBell, Inc. (NASDAQ:CBLL) shares climbed 8% on Monday after the company said it had received Breakthrough Device ...
The Breakthrough Device Designation for LVO Stroke represents the latest achievement in Ceribell’s continued efforts to extend its point-of-care EEG brain monitoring technology to additional ...
A lower-limb rehabilitation monitoring system for post-stroke patients developed by a group of five students has received a ...
Zacks Investment Research on MSN
CBLL wins FDA breakthrough status for AI-based LVO stroke detection
CeriBell Inc. CBLL recently announced that the FDA has granted Breakthrough Device Designation for its Large Vessel Occlusion ...
Ceribell announced today that the FDA granted breakthrough device designation for its large vessel occlusion (LVO) stroke ...
HELSINKI — Use of a novel algorithm significantly improved prehospital triage for stroke, more accurately directing appropriate patients to centers equipped for endovascular therapy (EVT) and boosting ...
Investing.com -- CeriBell, Inc. (NASDAQ:CBLL) stock jumped 8% on Monday after the medical technology company announced it received FDA Breakthrough Device Designation for its Large Vessel Occlusion ...
Most older adults prescribed gabapentin after a stroke kept getting the drug for at least 1 year. Gabapentin is used off-label for post-stroke pain, despite limited guidelines and safety concerns. The ...
MINNEAPOLIS — Roughly half of the patients experience headaches following a hemorrhagic stroke, with more than one third reporting severe pain — yet headache management remains a largely neglected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback